NEUVORA Labs

RESEARCH / CEREBRAL PALSY

Understanding the gap.
Defining the questions.

Our current focus is the potential role of biological markers in rehabilitation response in hypotonic cerebral palsy.

Based on the 2026 scoping review by David Šarlák
RESEARCH PROGRAMMEEVIDENCE MAPPING & PROPOSED DIRECTIONS

01 / THE SUBJECT

Hypotonic cerebral palsy.

The review uses “hypotonic CP” broadly, including predominantly low-tone presentations and the ataxic–hypotonic category used in some registries.

This is not a single, uniform biological profile. The manuscript highlights differences in diagnosis, motor presentation and possible underlying mechanisms as challenges for research.

Its central question is whether genetic, biochemical and imaging measurements could help explain differences in motor learning and response to rehabilitation in this population.

02 / THE EVIDENCE GAP

A hypothesis needs
its own evidence.

The review identifies a shortage of subtype-specific biomarker research. Findings from spastic CP and other neurological conditions cannot establish what works in hypotonic CP.

For example, a 2018 study of 33 children with unilateral spastic CP found an association between dopamine-related genetic variation and hand-training outcomes. That result does not validate the same score for hypotonic CP or for walking outcomes. Diaz Heijtz et al., 2018

The manuscript’s proposed next step is careful baseline characterisation, followed by prospective testing of candidate associations.

03 / PROPOSED RESEARCH AGENDA

Eight questions.
An open starting point.

Adapted from Section 8 of the preprint. These describe future studies, not ongoing experiments or established findings.

01What do neurotrophin and dopaminergic marker profiles look like in hypotonic CP?

Baseline biology

The review proposes descriptive profiling of growth factors and genetic markers, alongside clearly defined clinical characteristics and functional severity.

02How do motor and cerebellar pathways differ between CP groups?

Brain connectivity

The proposed agenda combines structural and functional imaging with biological measurements to explore how connectivity relates to clinical presentation.

03Could baseline BDNF or NGF levels help predict response to training?

Rehabilitation response

Prospective observational studies would measure biomarkers and motor outcomes before and after structured rehabilitation. A predictive relationship would need to be demonstrated.

04Do dopamine-related genetic scores relate to motor learning in hypotonic CP?

Dopamine genetics

This would extend a question studied in other populations to a specifically defined hypotonic CP cohort, including learning tasks with and without rewards.

05Does the balance of TrkB receptor forms matter?

Receptor biology

The review proposes exploratory work on full-length and truncated TrkB forms. Measurements outside the brain would need careful interpretation as indirect proxies.

06Could biomarker-based groups improve rehabilitation research?

Study design

Future feasibility studies could assess whether biological profiles help design more informative rehabilitation trials, before making any claims about clinical usefulness.

07Are there distinct patterns of rehabilitation response?

Individual differences

The proposed approach combines clinical information, imaging, genetic markers and biochemical measurements, including exploratory proteomics.

08How could meaningful biomarkers fit into everyday care?

Practical measurement

The review asks how repeated sampling, motor-learning tasks and wearable measurements might be studied in practical settings. These are proposed methods, not a validated clinical service.

04 / HOW AI COULD HELP

Computational thinking.
Empirical validation.

AI could support literature mapping, organise complex datasets and help generate hypotheses that researchers can test.

A useful model would need representative, appropriately collected data and independent validation. A simulation alone cannot establish whether a treatment is safe or effective, or replace clinical studies.

NEUVORA Labs does not currently offer a validated patient model or clinical prediction tool. Collaboration and sound study design come first.

Read the full study

LET’S CONNECT

Progress starts with
a conversation.

Get in touch